Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107637 | 0.94 | USP30 (0.49) | GPR119PDE4DPDE4BCHEK2P2RX3 | |
| SCHEMBL9891684 | 0.91 | GPR119 (0.51) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1107619 | 0.89 | GPR119 (0.49) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12594149 | 0.85 | USP30 (0.47) | GPR119PDE4DPDE4BCHEK2P2RX3 | |
| SCHEMBL22258415 | 0.84 | GPR119 (0.53) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL23465889 | 0.83 | GPR119 (0.63) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1107528 | 0.83 | USP30 (0.46) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL30955036 | 0.81 | GPR119 (0.56) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2969976 | 0.81 | GPR119 (0.56) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3156353 | 0.81 | GPR119 (0.49) | GPR119PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GPR119 18/4885PDE4D 1988/4885PDE4A 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.